Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM. Lim, M., Ye, X., Piotrowski, A. F., Desai, A., Ahluwalia, M., Walbert, T., Fisher, J. D., Desideri, S., Belcaid, Z., Jackson, C., Nabors, L. B., Wen, P. Y., Grossman, S. A. AMER SOC CLINICAL ONCOLOGY. 2019
View details for DOI 10.1200/JCO.2019.37.15_suppl.2017
View details for Web of Science ID 000487345804399